IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS

Immune checkpoint inhibitors are used with increasing regularity in metastatic disease. Anti-CTLA4 (ipilimumab) anti-PD1 (pembrolizumab, nivolumab) or anti-PD-L1(avelumab, atezolizumab) are approved for use in metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and other malignan...

Full description

Bibliographic Details
Main Authors: Ioana Cretu, Mihai Bojinca, Mihaela Milicescu, Bogdan Cretu, Ruxandra Ionescu
Format: Article
Language:English
Published: Amaltea Medical Publishing House 2018-12-01
Series:Romanian Journal of Medical Practice
Subjects:
immune checkpoint inhibitors
immune related adverse events
rheumatic disease
Online Access:https://revistemedicale.amaltea.ro/Romanian_Journal_of_RHEUMATOLOGY/Revista_Romana_de_REUMATOLOGIE-2018-Nr.4/RJR_2018_4_Art-01.pdf

Internet

https://revistemedicale.amaltea.ro/Romanian_Journal_of_RHEUMATOLOGY/Revista_Romana_de_REUMATOLOGIE-2018-Nr.4/RJR_2018_4_Art-01.pdf

Similar Items